News | Implantable Cardiac Monitor (ICM) | August 09, 2021

Biotronik Implantable Cardiac Monitor Receives Prestigious Industry Award

BioMonitor IIIm Received Frost & Sullivan’s ‘Enabling Technology Leadership Award’ 2021 for its High Precision Implantable Cardiac Monitoring

BioMonitor IIIm is a miniature electrocardiogram (ECG) device which records, stores and transmits clinical data that is integral in the diagnosis and long-term monitoring of cardiac patients, with maximum precision and for an extended period of time.

BioMonitor IIIm is a miniature electrocardiogram (ECG) device which records, stores and transmits clinical data that is integral in the diagnosis and long-term monitoring of cardiac patients, with maximum precision and for an extended period of time.


August 9, 2021 - In association with Heart Rhythm 2021, Biotronik today announced that the latest implantable cardiac monitor (ICM), BioMonitor IIIm, has been recognized by internationally-renowned research analysts Frost & Sullivan as high-performing across a range of innovation and customer value criteria.
 
The increased prevalence of cardiac disease, paired with the need to deliver more individualized and efficient healthcare, means that the use of ICMs, which remotely transmit vital clinical data, are now more important than ever. BioMonitor IIIm is a miniature electrocardiogram (ECG) device which records, stores and transmits clinical data that is integral in the diagnosis and long-term monitoring of cardiac patients, with maximum precision and for an extended period of time.
 
The key data ICMs need to deliver are high quality, reliable ECGs that cardiologists can rely upon to support an expedited and accurate diagnosis. BioMonitor IIIm's exclusive design is central to providing high rhythm fidelity and detection accuracy due to its high amplitude R-waves that average 0.7mVs that result in noise-free, reliable ECGs.
 
"This award recognizes that, Biotronik's innovative ICM design-integrating a flexible antenna-delivers superior, high definition ECGs with optimal P-wave visibility and larger signal amplitude," said David Hayes, M.D., Chief Medical Officer, Biotronik, Inc. "Higher amplitudes minimize signal noise to allow uninterrupted cardiac monitoring, enabling healthcare professionals to better diagnose and monitor patients around the clock."
 
Biotronik's ICM incorporates RhythmCheck, an algorithm which minimizes the instances of false positive atrial fibrillation (AF) detection. While AF sensitivity remains favorable, at 99.1 percent, while bradycardia, a-systole and sudden heart rate drop are maintained at 100 percent, the false detection rate is decreased, helping minimize the clinician workload associated with reviewing non-actionable ECGs in already stretched clinics.
 
"By allowing patients' recorded cardiac rhythm disturbance to be automatically and wirelessly transmitted to physicians, the solution enables 24-hour monitoring from anywhere. The transmission compliance rate of the Biotronik Home Monitoring solution is 98%, the highest in the industry," said Dr. M. Sneha Maria, Senior Research Analyst at Frost & Sullivan. "Such efficacy is useful, especially during the COVID-19 pandemic, as physicians can continually monitor patients for warning signs without hospital visits."
 
In its report, Frost & Sullivan also references BioMonitor IIIm's industry-leading battery life of five and a half years and how the device's flexible antenna, by design, adapts to the patient anatomy. In addition to providing a patient-centered remote monitoring experience. These design specifications are some of the unique features which help support an increased physician and patient experience.
 
Read the full Frost & Sullivan Enabling Technology Award 2021 report.

References: 
 
1. Mariani J et al. BIO|CONCEPT.BIOMONITOR III. Miniaturized implantable cardiac monitor with a long sensing vector (BIOMONITOR III): Insertion procedure assessment, sensing performance, and home monitoring transmission success. Journal of Electrocardiology. (2020).

2. Jensen MM, Brabrand M. The relationship between body temperature, heart rate and respiratory rate in acute patients at admission to a medical care unit. Scand J Trauma Resusc Emerg Med 23, A12 (2015). https://doi.org/10.1186/1757-7241-23-S1-A12.

3. Hayes, D, Reddy R and Whittington, H. Correlation of Vital Signs Facilitates Illness Screening in an Implantable Cardiac Monitor. BIOTRONIK, Inc., Lake Oswego, OR 2Micro Systems Engineering, Inc., Lake Oswego, ORAPHRS 2020.
 

Related Content

News | EP Lab

October 6, 2021 – Biosense Webster announced the first cases using a radiofrequency balloon ablation catheter were ...

Home October 06, 2021
Home
News | EP Lab
October 1, 2021 — The European Society of Cardiology (ESC) guidelines on cardiac pacing and cardiac resynchronization ...
Home October 04, 2021
Home
Videos | EP Lab
Khaldoun Tarakji, M.D., MPH, associate section head, cardiac electrophysiology, Heart and Vascular Institute at ...
Home October 04, 2021
Home
Feature | EP Lab

September 28, 2021 — New research from Washington University School of Medicine in St. Louis suggests that radiation ...

Home September 28, 2021
Home
News | EP Lab

September 1, 2021 — Stereotaxis and Shanghai Microport EP Medtech Co., Ltd. announced a broad collaboration to advance ...

Home September 01, 2021
Home
News | EP Lab

August 9, 2021 – Results from an international clinical trial show a significant reduction in risk of ventricular ...

Home August 09, 2021
Home
Feature | EP Lab

July 28, 2021 — Here is the complete list of late-breaking clinical trials (LBCT) and links to articles on all of them ...

Home August 09, 2021
Home
News | EP Lab | By Dave Fornell, Editor

August 5, 2021 — A prospective, non-randomized, multicenter, first-in-human clinical study found good diagnostic and ...

Home August 05, 2021
Home
News | EP Lab

August 3, 2021 — A subgroup analysis of the EAST – AFNET 4 study population revealed early initiation of rhythm control ...

Home August 03, 2021
Home
News | EP Lab

August 4, 2021 — Temporary Spinal cord stimulation (SCS) was effective in suppressing post-operative atrial fibrillation ...

Home August 03, 2021
Home
Subscribe Now